Skip to main content
main-content

Bone diseases

Osteoporosis

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

04-12-2018 | Comorbidities | Article

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study

Panopoulos S et al. Arthritis Res Ther 2018. doi: 10.1186/s13075-018-1771-0

19-11-2018 | Osteoporosis | Article

Risk of subsequent fracture after prior fracture among older women

Balasubramanian A et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4732-1

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

24-10-2018 | Osteoporosis | ACR/ARHP 2018 | News

Two-year data support denosumab use in patients with glucocorticoid-induced osteoporosis

Greater increases in bone mineral density seen with denosumab versus risedronate in glucocorticoid-treated patients with osteoporosis are sustained through 24 months, indicate phase III data.

03-10-2018 | Osteoarthritis | News

Diabetes linked to elevated arthritis, osteoporosis risk

Patients with diabetes have an increased risk for arthritis, osteoporosis, and musculoskeletal pain, study findings indicate.

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

This systematic review and meta-analysis were performed with the aim to quantify the risk of hip fracture associated with proton pump inhibitor use [read more].
Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

29-08-2018 | Osteoporosis | Review | Article

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

07-08-2018 | Rheumatoid arthritis | News

Disease activity linked to osteoporotic fracture risk in RA patients

Patients with rheumatoid arthritis who have high cumulative disease activity and functional disability have an elevated 10-year risk for osteoporotic fracture, researchers report.

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

This study aimed to examine the relationship between medication persistence and fracture risk among female Medicare beneficiaries diagnosed with osteoporosis [read more].
Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

31-07-2018 | Osteoporosis | News

'Dismal' rates of osteoporosis treatment initiation after hip fracture

The proportion of patients initiating osteoporosis medication following hip fracture has declined in recent years, despite treatment reducing subsequent fracture risk, analysis of a US medical claims database suggests.

30-07-2018 | Osteoporosis | Review | Article

Glucocorticoid-induced osteoporosis: Update on management

Jagpal A, Saag KG. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0105-3

23-07-2018 | Osteoporosis | Article

Incidence, risk factors, and fracture healing of atypical femoral fractures: A multicenter case-control study

Lim SJ et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4640-4

20-07-2018 | Osteoporosis | Article

Incidence of subsequent fractures in the UK between 1990 and 2012 among individuals 50 years or older

van der Velde RY et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4636-0

18-07-2018 | Osteoporosis | Article

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

17-07-2018 | Osteoporosis | Review | Article

Denosumab in the treatment of glucocorticoid-induced osteoporosis

Coskun Benlidayi I. Rheumatol Int 2018. doi: 10.1007/s00296-018-4106-1

26-06-2018 | Osteoporosis | News

USPSTF issues recommendations for osteoporosis screening

The US Preventive Services Task Force has published a recommendation statement on screening for osteoporosis to reduce fracture risk.

image credits